Navigation Links
Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients
Date:10/30/2008

transplantation in the United States. Due to the asymptomatic nature of HCV infection, it often goes undetected for up to 20 years following initial infection. Each year, 8,000 to 10,000 people in the United States die from complications of HCV.

The current standard of care is a combination of pegylated interferon and ribavirin. Inadequate response rates, in particular for patients infected with genotype 1 HCV, along with significant side effects of approved therapy support the medical need for improved treatment options. It is estimated that fewer than 5% of people with chronic HCV infection living in the United States are under treatment today. Most infected individuals are unaware of their infection status and the large majority of individuals who know their condition do not currently receive drug therapy. There is also a growing number of individuals who have failed interferon-based regimens who may be successfully treated with combinations of two or more direct antivirals. It is expected that the next generation of therapies for treatment of HCV will include small molecules, such as ANA598, that directly act upon specific viral enzymes to inhibit viral replication and orally administered agents such as ANA773, which are being developed to potentially replace injectable interferon. These new therapies are expected to improve overall therapy by increasing cure rates and potentially improving tolerability and convenience of treatment if doses of currently used agents can be reduced or eliminated.

About Anadys

Anadys Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology. For the treatment of chronic hepatitis C, the Company is developing two potentially complementary agents: ANA598, a non-nucleoside polymerase inhibitor and ANA773, an oral TLR7 agonist prodrug. The Company is also developing ANA773 for the treatment of cance
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... 2015 In today,s fast changing healthcare ... drive positive health outcomes, improve profitability and enhance ... care in their communities. At ThoughtSpot 2015, ... AmerisourceBergen announced a new set of innovative capabilities ... and help independent pharmacies endure the industry,s most ...
(Date:7/30/2015)... ... July 31, 2015 , ... Ralco is honored to announce that it ... Fair to be held August 5-9 in Marshall. The Ralco Enrichment Center is an ... and how agriculture impacts their daily lives. This unique exhibit also features a birthing ...
(Date:7/30/2015)... ... ... The 2015 Market Research Report on the Global Propanol Industry ... market with a focus on the Chinese situation. Major companies included in the propanol ... Sanofi, Royal Dutch Shell, LG Chem and Zhejiang Xinhua Chemical. , The report provides ...
(Date:7/30/2015)...   Senomyx , Inc. (NASDAQ: SNMX ), ... discover, develop, and commercialize novel flavor ingredients for the ... results for the second quarter 2015. ... on track to achieve our commercial and financial goals," ... the Company. "Since our last quarterly earnings report, our ...
Breaking Biology Technology:AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 3Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9
... /Xinhua-PRNewswire-FirstCall/ -- 3SBio Inc.,(Nasdaq: SSRX ), a ... and marketing biopharmaceutical,products, today announced its unaudited financial ... Second Quarter 2008 Financial Highlights: ... second quarter 2007 to ...
... To protect potential patients from,being unwitting victims in ... Stem Cell Institute LLC (RSCI),( http://www.RepairStemCells.org ) and ... of the industry,s first standards of,excellence for Repair ... RSC, also known as Adult Stem Cells. Among ...
... on Monday, August 18, 2008, ... Beginning at 1:00 PM Eastern Time, LIVINGSTON, N.J., Aug. ... in,advanced injection technologies, today announced that it plans to report,its results ... the morning,of Thursday, August 14, 2008., Milestone Scientific will also ...
Cached Biology Technology:3SBio Inc. Announces Second Quarter 2008 Results 23SBio Inc. Announces Second Quarter 2008 Results 33SBio Inc. Announces Second Quarter 2008 Results 43SBio Inc. Announces Second Quarter 2008 Results 53SBio Inc. Announces Second Quarter 2008 Results 63SBio Inc. Announces Second Quarter 2008 Results 73SBio Inc. Announces Second Quarter 2008 Results 83SBio Inc. Announces Second Quarter 2008 Results 93SBio Inc. Announces Second Quarter 2008 Results 103SBio Inc. Announces Second Quarter 2008 Results 113SBio Inc. Announces Second Quarter 2008 Results 123SBio Inc. Announces Second Quarter 2008 Results 133SBio Inc. Announces Second Quarter 2008 Results 143SBio Inc. Announces Second Quarter 2008 Results 15Repair Stem Cell Institute Announces Industry's First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics 2Milestone to Report Results for 2008 Second Quarter on Thursday, August 14, 2008 2
(Date:7/31/2015)... SHENZHEN, China , 31 de julho de 2015 ... Genômica (ICG-10, www.icg-10.org ) será realizada pela BGI de ... China . A conferência está ... inauguração em 2006, a ICG se tornou uma das ... e um dos encontros científicos mais dinâmicos, entusiastas e ...
(Date:7/31/2015)... --NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... mobile commerce market and creator of the Wocket® smart ... for ELECTRONIC CRYPTO-CURRENCY MANAGEMENT METHOD AND SYSTEM ... crypto-currencies such as Bitcoin into the consumer market of ... manage all payments.  The technology manages ...
(Date:7/27/2015)... 2015   Zynx Health ™, the market ... solutions, today announced that its ZynxCarebook ™ ... Android smartphones and tablets. With this expansion, care ... use ZynxCarebook to securely exchange messages and share ... transitions to other care settings, and improve clinical ...
Breaking Biology News(10 mins):A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3
... Jan. 6, 2011 Acceleron Pharma, Inc., a biopharmaceutical ... cells and tissues including muscle, bone, fat, red blood ... awarded a $1.5 million grant from the Muscular Dystrophy ... Muscular Dystrophy (DMD), a disabling neuromuscular disease in which ...
... that nations should abandon the concept of carbon emissions ... might lead to genuine reductions in the amount of ... provide a mechanism for reducing climate change. Details of ... Interdisciplinary Environmental Review . Carbon emissions trading ...
... The number of women who die from complications of ... last two decades thanks to improved monitoring and better ... report,s lead researcher, Joy Hawkins, MD, professor of anesthesiology ... Colorado School of Medicine, said the risks have been ...
Cached Biology News:Acceleron awarded $1.5 million grant from Muscular Dystrophy Association to support ACE-031 2Carbon swap bank to beat climate change 2Carbon swap bank to beat climate change 3Deaths from anesthesia during childbirth plummet 2
... Measurement of light production by luciferase-cDNA ... a valuable technique in the development of ... is used as an indicator for the ... the luciferase enzyme is due to advantages ...
... detection of apoptosis and mitochondrial membrane potential. ... early indication of the initiation of cellular ... a collapse in the electrochemical gradient across ... change in the membrane potential (YD). Loss ...
... kit measures mitochondria intactness and detects ... potential. Features and Benefits: ... staining isolated mitochondria and for assaying ... the reagents required for the detection ...
... is expressed in g per ml and is ... pH 6.8, of a 1 mg per ml ... concentration to agglutinate a 2% suspension of human ... at 25 C. Preparation Note: Affinity ...
Biology Products: